SCHEMBL22925907

SCHEMBL22925907

COc1ccc(COc2cc(Nc3nc(C)c(-c4ccc(C(F)(F)F)cc4)o3)cnc2C#N)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 1/20 0.42
▸ PDE2A O00408 1/20 0.41
▸ PPARD Q03181 2/20 0.40
▸ MAPT P10636 7/20 0.39
▸ HPGD P15428 5/20 0.39
▸ TP53 P04637 3/20 0.39
▸ HTT P42858 2/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ LMNA P02545 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ PSEN1 P49768 1/20 0.37
▸ PSEN2 P49810 1/20 0.37
▸ APH1B Q8WW43 1/20 0.37
▸ NCSTN Q92542 1/20 0.37
▸ APH1A Q96BI3 1/20 0.37
▸ PSENEN Q9NZ42 1/20 0.37
▸ KIT P10721 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22926079 0.86 IMPDH2 (0.45) GSK3BPDE2AMAPTHPGDTP53
SCHEMBL29620874 0.86 IMPDH2 (0.45) GSK3BPDE2AMAPTHPGDTP53
SCHEMBL22925905 0.83 PPARD (0.41) GSK3BPDE2APPARDPSEN1PSEN2
SCHEMBL28733796 0.83 PPARD (0.41) GSK3BPDE2APPARDPSEN1PSEN2
SCHEMBL22925755 0.80 IMPDH2 (0.38) GSK3BPDE2AMAPTHPGDTP53
SCHEMBL29620887 0.80 IMPDH2 (0.38) GSK3BPDE2AMAPTHPGDTP53
SCHEMBL29696282 0.77 IMPDH2 (0.41) MAPTHPGDTP53HTTALOX15
SCHEMBL22925794 0.77 IMPDH2 (0.41) MAPTHPGDTP53HTTALOX15
SCHEMBL22925750 0.75 CHEK1 (0.38) PDE2AKITCHEK1CSF1R
SCHEMBL29621090 0.75 CHEK1 (0.38) PDE2AKITCHEK1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 — — CN disclosed
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 — — US disclosed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 — — EP disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 — — CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB GSK3B 605/4885PDE2A 2451/4885PPARD 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback